US Oncology Research Affiliated Physicians to Present at 2011 ASCO Annual Meeting

The four studies being presented orally at ASCO by US Oncology Research affiliated physicians are as follows:

Frankie Ann Holmes, MD, Texas Oncology

Sunday, June 5, 9:45 AM - 10:00 AM, Hall B1

Correlation of molecular effects and pathologic complete response to preoperative lapatinib and trastuzumab, separately and combined prior to neoadjuvant breast cancer chemotherapy.

John Pippen, MD, FACP, Texas Oncology

Sunday, June 5, 4:30 PM - 4:45 PM, Hall B1

Randomized, phase III study of adjuvant doxorubicin + cyclophosphamide (AC) --> docetaxel (T) +/- capecitabine (X), in high-risk EBC: Exploratory Ki-67 analyses.

Joyce O'Shaughnessy, MD, Texas Oncology

Monday, June 6, 11:00 AM - 11:15 AM, Hall B1

A randomized phase III study of iniparib (BSI-201) in combination with gemcitabine/carboplatin (G/C) in metastatic triple-negative breast cancer (TNBC).

Robert Jotte, MD, PhD, Rocky Mountain Cancer Centers

Tuesday, June 7, 8:00 AM - 8:15 AM, Arie Crown Theater

Randomized phase III trial of amrubicin versus topotecan (Topo) as second-line treatment for small cell lung cancer (SCLC).

Oral Presentations:

Thomas Cartwright, MD, Ocala Oncology Center

Saturday, June 4, 2:45 PM – 3:00 PM, Hall D1

A multinational, randomized phase III study of bevacizumab (Bev) with FOLFOX4 or XELOX versus FOLFOX4 alone as adjuvant treatment for colon cancer (CC): Subgroup analyses from the AVANT trial.

Thomas E. Hutson, DO, PharmD, FACP, Texas Oncology

Saturday, June 4, 4:00 PM – 4:15 PM, Arie Crown Theater

BRIM-2: An open-label, multicenter phase II study of RG7204 (PLX4032) in previously treated patients with BRAF V600E mutation-positive metastatic melanoma.

Michael Teneriello, MD, FACOG, Texas Oncology

Saturday, June 4, 4:15 PM - 4:30 PM, E354a          

OCEANS: A randomized, double-blinded, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab (BEV) in patients with platinum-sensitive recurrent epithelial ovarian (EOC), primary peritoneal (PPC), or fallopian tube cancer (FTC).

Jerome Goldschmidt, MD, Blue Ridge Cancer Care

Sunday, June 5, 10:00 AM - 10:15 AM, Hall D1

Final efficacy results from OAM4558g, a randomized Phase II study evaluating MetMAb or placebo in combination with Erlotinib in advanced NSCLC.

Daniel D. Von Hoff, MD, FACP, TGen, Scottsdale Healthcare, US Oncology Research

Sunday, June 5, 11:00 AM - 11:15 AM, Arie Crown Theater

Safety, pharmacokinetics, and pharmacodynamics results from a phase I trial of BAY 86-9766 (RDEA119), a MEK inhibitor, in patients with advanced cancer.

Thomas E. Hutson, DO, PharmD, FACP, Texas Oncology

Sunday, June 5, 11:50 AM - 12:10 PM, Hall D2

Management of Unique Subsets of Patients with Renal Cell Cancer.

Nicholas Vogelzang, MD, Comprehensive Cancer Centers of Nevada

Alexander Spira, MD, Virginia Cancer Specialists

Sunday, June 5, 12:00 PM - 12:15 PM, Arie Crown Theater

Cabozantinib (XL184) has activity in both soft tissue & bone: Results of a phase 2 randomized discontinuation trial (RDT) in patients (pts) w/ advanced solid tumors.

Thomas E. Hutson, DO, PharmD, FACP, Texas Oncology

Monday, June 6, 8:00 AM - 8:15 AM, Hall D2

Axitinib versus sorafenib as second-line therapy for metastatic renal cell carcinoma (mRCC): Results of phase III AXIS trial.

Jeff Sharman, MD, Willamette Valley Cancer Institute and Research Center

Donald Richards, MD, PhD, Texas Oncology

Monday, June 6, 9:30 AM - 12:30 PM, Arie Crown Theater

Activity and tolerability of the Bruton's tyrosine kinase (Btk) inhibitor PCI-32765 in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): Interim results of a phase Ib/II study.

Alexander Spira, MD, Virginia Cancer Specialists

Nicholas Vogelzang, MD, Comprehensive Cancer Centers of Nevada

Monday, June 6, 1:15 PM - 1:30 PM, Hall D1

Cabozantinib (XL184) in metastatic castration-resistant prostate cancer (mCRPC): Results from a phase II randomized discontinuation trial.

Poster Discussions:

Daniel D. Von Hoff, MD, FACP, TGen, Scottsdale Healthcare, US Oncology Research

Poster #23

Saturday, June 4, 8:00 AM – 12:00 PM, S403

Discussion

12:00 PM – 1:00 PM, S406

Phase I clinical trial of VTX-2337, a selective toll-like receptor 8 (TLR8) agonist, in patients with advanced solid tumors.

Daniel D. Von Hoff, MD, FACP, TGen, Scottsdale Healthcare, US Oncology Research

Poster #5

Saturday, June 4, 2:00 PM - 6:00 PM, S403

Discussion

5:00 PM - 6:00 PM, S406

Phase I study of the multikinase prodrug SF1126 in solid tumors and B-cell malignancies.

Guru Sonpavde, MD, Texas Oncology

Mark Fleming, MD, Virginia Oncology Associates

Thomas E. Hutson, DO, PharmD, FACP, Texas Oncology

Poster #8

Saturday, June 4, 2:00 PM - 6:00 PM, E450a

Discussion

5:00 PM - 6:00 PM, Hall D

A randomized, double-blind phase II trial of docetaxel plus prednisone (DP) combined with either AT-101 or placebo for the first-line therapy of metastatic castration-resistant prostate cancer (CRPC).

Thomas E. Hutson, DO, PharmD, FACP, Texas Oncology

Poster #17

Saturday, June 4, 2:00 PM - 6:00 PM, S103

Discussion

5:00 PM - 6:00 PM, S100bc

Circulating protein biomarkers of sunitinib and interferon efficacy in treatment naive patients with metastatic renal cell carcinoma.

Carlos Becerra, MD, Texas Oncology

Poster #14

Monday, June 6, 8:00 AM - 12:00 PM, E450b

Discussion

11:30 AM - 12:30 PM, Hall D1

Phase II trial of figitumumab in patients with refractory, metastatic colorectal cancer (mCRC).

Donald Richards, MD, PhD, Texas Oncology

Darren M Kocs, MD, Texas Oncology

Alexander Spira, MD, Virginia Cancer Specialists

David McCollum, MD, Texas Oncology

Kristi Boehm, Feng Zhan, PhD, Lina Asmar, PhD, US Oncology Research

Poster #8

Monday, June 6, 2:00 PM - 6:00 PM, E450b

Discussion

5:00 PM - 6:00 PM, Hall D1

Results of docetaxel plus oxaliplatin (DOCOX) +/- cetuximab in patients with metastatic gastric and/or gastroesophagel junction adenocarcinoma; results of a randomized phase II study.

Donald Richards, MD, PhD, Texas Oncology

Poster #11

Monday, June 6, 2:00 PM - 6:00 PM, E450b

Discussion

5:00 PM - 6:00 PM, Hall D1

Randomized phase II study (GATE study) of docetaxel plus oxaliplatin with or without fluorouracil or capecitabine in metastatic or locally recurrent gastric cancer.

Guru Sonpavde, MD, Texas Oncology

Nicholas Vogelzang, MD, Comprehensive Cancer Centers of Nevada

Peter Rosen, MD, Roy & Patricia Disney Cancer Research Center

Alexander Spira, MD, Virginia Cancer Specialists

Poster #22

Tuesday, June 7, 8:00 AM - 12:00 PM, E450b

Discussion

11:30 AM - 12:30 PM, E354a

Clinical outcome of single agent volasertib (BI 6727) as second-line treatment of patients (pts) with advanced or metastatic urothelial cancer (UC).      

Posters:

Joyce O'Shaughnessy, MD, Texas Oncology

Thomas Cartwright, MD, Ocala Oncology Center

Poster #21C

Saturday, June 4, 8:00 AM - 12:00 PM, Hall A

Effect of dose modification on the efficacy of capecitabine: Data from six randomized, phase III trials in patients with colorectal or breast cancer.

Joe Stephenson, MD, Cancer Centers of the Carolinas

Donald Richards, MD, PhD, Texas Oncology

Carlos Becerra, MD, Texas Oncology

Poster #36H

Saturday, June 4, 8:00 AM - 12:00 PM, Hall A

The safety of IPI-926, a novel hedgehog pathway inhibitor, in combination with gemcitabine in patients (pts) with metastatic pancreatic cancer.

Nicholas Robert, MD, Virginia Cancer Specialists

Poster #43C

Saturday, June 4, 8:00 AM - 12:00 PM, Hall A

Utilization and clinical practice impact of an interactive tool for guiding choice of systemic adjuvant treatment (adj TX) for patients with early breast cancer (EBC).

Craig Reynolds, MD, Ocala Oncology Center

Alexander Spira, MD, Virginia Cancer Specialists

Larry Gluck, MD, Cancer Centers of the Carolinas

Robert Pluenneke, MD, Kansas City Cancer Centers

Kristi Boehm, Feng Zhan, PhD, Lina Asmar, PhD, US Oncology Research

Poster #33E

Saturday, June 4, 2:00 PM - 6:00 PM, Hall A

Results of a phase II study of single-agent sunitinib in elderly non-small cell lung cancer patients.

Ruth Oratz, MD, FACP, The Women's Oncology & Wellness Practice

Poster #1B

Saturday, June 4, 2:00 PM - 6:00 PM, Hall A

Recruitment in the internet era: An efficient strategy for studying breast cancer risk.

Daniel D. Von Hoff, MD, FACP, TGen, Scottsdale Healthcare, US Oncology Research

Poster #9F

Sunday, June 5, 8:00 AM - 12:00 PM, Hall A

A phase I dose escalation study of NKP-1339 in patients with advanced solid tumors refractory to treatment.

William Berry, MD, Cancer Centers of North Carolina

Guru Sonpavde, MD, Texas Oncology

Poster #2E

Sunday, June 5, 8:00 AM - 12:00 PM, Hall A

Evaluating the value of continuing docetaxel and prednisone (DP) beyond 10 cycles in men with metastatic castration-resistant prostate cancer (mCRPC).

Guru Sonpavde, MD, Texas Oncology

Poster #2F

Sunday, June 5, 8:00 AM - 12:00 PM, Hall A

Association of progression-free survival (PFS) at 2 or 3 years with overall survival (OS) at 5 years for locally advanced bladder cancer (BC): Evaluation of individual patient data (IPD) from seven randomized trials comparing local therapy with or without neoadjuvant chemotherapy (NC).

Thomas E. Hutson, DO, PharmD, FACP, Texas Oncology

Poster #5D

Sunday, June 5, 8:00 AM - 12:00 PM, Hall A

A pooled analysis of the efficacy and safety of sunitinib in elderly patients with metastatic renal cell carcinoma.

Thomas E. Hutson, DO, PharmD, FACP, Texas Oncology

Poster #6B

Sunday, June 5, 8:00 AM - 12:00 PM, Hall A

Analysis of the relationship between KPS and tumor response in the RECORD-1 phase III trial of everolimus in patients with advanced renal cell carcinoma.

Thomas E. Hutson, DO, PharmD, FACP, Texas Oncology

Poster #9A

Sunday, June 5, 8:00 AM - 12:00 PM, Hall A

Very low incidence of thyroid dysfunction in renal cell carcinoma patiens treated with pazopanib in prospective clinical trials.

Guru Sonpavde, MD, Texas Oncology

Poster #13F

Sunday, June 5, 8:00 AM - 12:00 PM, Hall A

Results of a phase I/II clinical trial of BPX-101, a novel drug-activated dendritic cell (DC) vaccine for metastatic castration-resistant prostate cancer (mCRPC).

Michael Teneriello, MD, FACOG, Texas Oncology

John R. Caton, MD, Willamette Valley Cancer Institute and Research Center

Robert H. Gersh, MD, Cancer Care Northwest

Poster #15A

Sunday, June 5, 8:00 AM - 12:00 PM, Hall A    

PRECEDENT: A randomized phase II trial comparing EC145 and pegylated liposomal doxorubicin (PLD) in combination, versus PLD alone, in subjects with platinum-resistant ovarian cancer.

Daniel D. Von Hoff, MD, FACP, TGen, Scottsdale Healthcare, US Oncology Research

Poster #16A

Monday, June 6, 8:00 AM - 12:00 PM, Hall A

First in human study with ARQ 621, a novel inhibitor of Eg5: final results from the solid tumors cohort.

Daniel D. Von Hoff, MD, FACP, TGen, Scottsdale Healthcare, US Oncology Research

Poster #17D

Monday, June 6, 8:00 AM - 12:00 PM, Hall A

Findings from the phase I clinical trials of CX-4945, an orally available inhibitor of CK2.

Stephen Anthony, DO, Evergreen Hematology and Oncology

Daniel D. Von Hoff, MD, FACP, TGen, Scottsdale Healthcare, US Oncology Research

Poster #18B

Monday, June 6, 8:00 AM - 12:00 PM, Hall A

Pharmacodynamic activity demonstrated in phase I for PLX3397, a selective inhibitor of FMS and Kit.

Kavita Sail, MS, PhD, Healthcare Informatics, US Oncology

Melissa Halm, MPH, Healthcare Informatics, US Oncology

Debra Patt, MD, MPH, Texas Oncology

Poster #12B

Monday, June 6, 1:00 PM - 5:00 PM, Hall A

Treatment patterns in patients with HER2-positive early-stage breast cancer (ESBC) receiving adjuvant treatment with a trastuzumab-containing regimen.

Clara Chen, MS, Healthcare Informatics, US Oncology

Debra Patt, MD, MPH, Texas Oncology

Michael Forsyth, RPh, MBA, Rocky Mountain Cancer Centers

Denise Kazzaz, Jeff Shankleton, Ramachandran Ganesh, Healthcare Informatics, US Oncology

Poster #12C

Monday, June 6, 1:00 PM - 5:00 PM, Hall A

Evaluating utilization characteristics for the Oncotype DX recurrence score in early-stage breast cancer.

Nicholas Robert, MD, Virginia Cancer Specialists

Joyce O'Shaughnessy, MD, Texas Oncology

Poster #19E

Monday, June 6, 1:00 PM - 5:00 PM, Hall A

Capecitabine (X) in the first-line treatment of metastatic breast cancer (MBC).

Karen Tedesco, MD, New York Oncology Hematology

Joanne Blum, MD, Texas Oncology

Cynthia Osborne, MD, Texas Oncology

Frankie Ann Holmes, MD, Texas Oncology

Poster #25B

Monday, June 6, 1:00 PM - 5:00 PM, Hall A

Final results of a phase II trial of trabectedin (T) in triple-negative, HER2-positive and BRCA1/2 germ-line-mutated metastatic breast cancer (MBC) patients (pts).

Robert Rifkin, MD, FACP, Rocky Mountain Cancer Centers

Poster #48D

Monday, June 6, 1:00 PM - 5:00 PM, Hall A

Impact of baseline characteristics on efficacy and safety after bortezomib-based induction and maintenance in newly diagnosed multiple myeloma patients ineligible for transplant in the phase 3b UPFRONT study.

Trials in Progress:

Joanne Blum, MD, Texas Oncology

Poster #37D

Monday, June 6, 8:00 AM - 12:00 PM, Hall A

A phase II study of ridaforolimus (RIDA) and dalotuzumab (DALO) in estrogen receptor positive-(ER+) breast cancer.

Allen Cohn, MD, Rocky Mountain Cancer Centers

Linda DeMarco, MD, FACP, New York Oncology Hematology

Jean Stephenson, RN, Texas Oncology

Brian Ulrich, MD, Texas Oncology

Peter Yu, MD, Camino Medical Group

Poster #45F

Monday, June 6, 8:00 AM - 12:00 PM, Hall A

Randomized phase II study of the efficacy and safety of gemcitabine + TH-302 vs gemcitabine alone in previously untreated patients with advanced pancreatic cancer.

Frankie Ann Holmes, MD, Texas Oncology

Poster #40G

Monday, June 6, 8:00 AM - 12:00 PM, Hall A

A phase 3 trial of adjuvant neratinib (NER) after trastuzumab (TRAS) in women with early-stage HER2+ breast cancer (BC).

Thomas E. Hutson, DO, PharmD, FACP, Texas Oncology

Poster #47H

Monday, June 6, 8:00 AM - 12:00 PM, Hall A

Phase I/II study of BNC105P in combination with everolimus or following everolimus for progressive metastatic renal cell carcinoma following prior tyrosine kinase inhibitors.

Publish Only:

Joyce O'Shaughnessy, MD, Texas Oncology

Eribulin mesylate EMBRACE study: Survival analysis excluding patients rechallenged with therapies of the same class.

Thomas E. Hutson, DO, PharmD, FACP, Texas Oncology

Phase III study of axitinib versus sorafenib for treatment of patients with metastatic renal cell carcinoma.  TRIAL in PROGRESS.

William Berry, MD, Cancer Centers of North Carolina

Mark Fleming, MD, Virginia Oncology Associates

Michael Kolodziej, MD, New York Oncology Hematology

Sanjiv Awasthi, Texas Oncology

Thomas E. Hutson, DO, PharmD, FACP, Texas Oncology

Danko Martincic, MD, Cancer Care Northwest

Guru Sonpavde, MD, Texas Oncology

Yunfei Wang, Lina Asmar, PhD, US Oncology Research

Association of rash with improved outcomes by the addition of cetuximab (C) to second-line mitoxantrone plus prednisone (MP) for progressive mCRPC after docetaxel-based chemotherapy.

Nicholas Vogelzang, MD, Comprehensive Cancer Centers of Nevada

Paul Conkling, MD, Virginia Oncology Associates

Manuel Modiano, MD, Arizona Oncology Associates

An open-label, multicenter, randomized Phase Ib/II study of eribulin mesylate administered in combination with gemcitabine plus cisplatin versus gemcitabine plus cisplatin alone as first line therapy for locally advanced or metastatic bladder cancer.

Marcus Neubauer, MD, Jody S. Garey, PharmD, Greg Nelson, Debra Patt, MD, Tom Cartwright, MD, Russ Hoverman, MD, Leslie T. Busby, MD, Barry Brooks, MD, Mark Sitarik, MD, Mike Kolodziej, MD, Roger Anderson Dr PH, Roy Beveridge, MD; on behalf of the US Oncology Pathways Task Force and Clinical Content Development Team

Bevacizumab therapy in advanced non-small cell lung cancer (NSCLC):  outcomes from a community oncology network.

Mark Fleming, MD, Virginia Oncology Associates

John Burke, MD, Rocky Mountain Cancer Centers

John R. Caton, MD, Willamette Valley Cancer Institute and Research Center

Guru Sonpavde, MD, Texas Oncology

Ability of serum alkaline phosphatase (ALP) changes to complement PSA changes and predict survival in men with metastatic castration-resistant prostate cancer (mCRPC) receiving docetaxel and prednisone (DP).

Aimee L. Ginsburg, PharmD, Debra M. Patt MD, Jennifer Flinn, Janet L. Espirito, PharmD, Marcus A. Neubauer, MD, J. Russell Hoverman, MD, PhD, Thomas H. Cartwright, MD, Leslie T. Busby, MD, Barry Don Brooks, MD, Michael A. Kolodziej, MD, Mark A. Sitarik, MD; on behalf of the US Oncology Pathways Task Force and Clinical Content Development Team

Understanding Male Breast Cancer in the Community Setting.

Debra Patt, MD, Janet Espirito, PharmD, Brian Turnwald, J. Russell Hoverman, MD, Marcus Neubauer, MD, Thomas Cartwright, MD, Barry Brooks, MD, Leslie Busby, MD, Mark Sitarik, MD, Michael Kolodziej, MD, Aimee Ginsburg, PharmD, Sheetal Sheth, PharmD, Jody Garey, PharmD, Matthew Clayton, Greg Nelson, Roger Anderson, DrPH, Roy Beveridge, MD; on behalf of the US Oncology Pathways Task Force and Clinical Content Development Team

Utilization and relative value of breast cancer adjuvant chemotherapy regimens in the community.

Avani Joshi, PhD, Healthcare Informatics, US Oncology

David Fryefield, MD, Willamette Valley Cancer Institute and Research Center

Michael Forsyth, RPh, MBA, Rocky Mountain Cancer Centers

William Lopez, Healthcare Informatics, US Oncology

Demographic and treatment characteristics for advanced basal cell carcinoma (aBCC) in an oncology outpatient setting.

Thomas Cartwright, MD, Ocala Oncology Center

Michael Forsyth, RPh, MBA, Rocky Mountain Cancer Centers

Heather Hartnett, PhD, Hsingwen Chung, MS, Melissa Halm, MPH, Healthcare Informatics, US Oncology

mCRC - Survival Outcomes with the use of Bevacizumab beyond progression in metastatic colorectal cancer patients.

Clara Chen, MS, Healthcare Informatics, US Oncology

Debra Patt, MD, MPH, Texas Oncology

Michael Forsyth, RPh, MBA, Rocky Mountain Cancer Centers

Denise Kazzaz, Jeff Shankleton, Ramachandran Ganesh, Healthcare Informatics, US Oncology

Evaluation of relation between Oncotype DX recurrence score and adjuvant chemotherapy administration.

Kavita Sail, MS, PhD, Healthcare Informatics, US Oncology

Debra Patt, MD, MPH, Texas Oncology

Michael Forsyth, RPh, MBA, Rocky Mountain Cancer Centers

Melissa Halm, MPH, William Lopez, Healthcare Informatics, US Oncology

Patterns of Care and Patient Characteristics in Post-menopausal Women with HER2+ and Hormone Receptor Positive (HR+) Metastatic Breast Cancer (MBC).

Dean Gesme, MD, FACP, FACPE, Minnesota Oncology

Risk of treatment failure after first-line tyrosine kinase inhibitors (TKI) therapy in patients with metastatic renal cell carcinoma.

Joanne Blum, MD, Texas Oncology

Capecitabine (Cap) monotherapy in anthracycline (A)-/taxane – (T) pretreated MBC.

Presentations from McKesson:

Poster:

Zhaohui Wang, McKesson Specialty Care Solutions

Poster #32B

Saturday, June 4, 2:00 PM – 6:00 PM, Hall A

Guideline adherence rates and costs of chemotherapy treatment for NSCLC patients treated in U.S. community oncology practices.

Publish Only:

Brandon Tom, McKesson Corporation

Leveraging technology and data to facilitate development of cost-effective pathways.